Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection By ef Posted 09/27/2022 In Scientific publications Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection2022-09-272022-09-27http://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.pngNouscomhttp://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.png200px200px D’Alise AM et al. Sci Transl Med 2022 Read article Recent PostsNouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer ImmunotherapyNOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical ScienceNouscom announces appointment of Yen-Ching Chua as Vice President of Clinical Operations
